IN8bio, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Tai-Wei
- Full Time Employees
- 18
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 350 5th Avenue New York City NY United States of America 10118
- IPO Date
- Jul 30, 2021
- CIK
- 0001740279
- Website
- in8bio.com
- Similar Companies
- Business
- IN8bio, Inc. is a clinical-stage biotechnology company primarily engaged in developing cell and gene therapies for patients with unmet medical needs in oncology and autoimmune diseases. The company focuses on proprietary cell therapy product candidates, including stromal vascular fraction (SVF) cell therapies and autologous T-cell therapies. Its pipeline comprises products targeting solid tumors, hematologic malignancies, and autoimmune disorders. IN8bio offers cell manufacturing services and research collaborations to support its therapeutic development programs. The company operates mainly in the United States and is headquartered in Woburn, Massachusetts. Founded in 2017, IN8bio aims to leverage its proprietary technologies and strategic partnerships to advance its pipeline and expand therapeutic applications. Recently, IN8bio has undertaken significant strategic shifts including advancing its product pipeline with new clinical trials and expanding its cell therapy manufacturing capabilities. The company has engaged in research collaborations and partnerships to broaden its technological platform and product reach. It also focuses on new product launches within its SVF and T-cell therapy segments aimed at oncology and autoimmune diseases. These operational developments reflect IN8bio's concerted effort to position itself as a competitive cell and gene therapy innovator in a rapidly evolving biotechnology landscape. No major name changes or reorganizations have been reported in the last two years. The company remains committed to advancing clinical-stage programs and scaling manufacturing to support future commercial activities. IN8bio serves primarily pharmaceutical partners, healthcare institutions, and clinical trial entities across North America. Its business segments include cell therapy development, contract manufacturing, and collaborative research services. The company’s product categories encompass autologous cell therapies, gene-modified T-cell candidates, and SVF-based therapeutic candidates. As an emerging biotech firm, IN8bio positions itself at the intersection of advanced regenerative medicine and immuno-oncology.
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB)
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
IN8bio to Present at TD Cowen 46th Annual Health Care Conference
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
IN8bio (NASDAQ:INAB) & Cadrenal Therapeutics (NASDAQ:CVKD) Head to Head Review
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025